Blockbuster deals push med-tech M&A above $40B in Q1 2026

April 2, 2026

Med-tech deal value, excluding M&As, totaled $628.41 million in the first quarter (Q1) of 2026, an increase of about 322% from the $149.08 million recorded in Q1 2025 though a 36% drop from Q4 2025‘s $978.58 million.

BioWorld Analysis and data insight Deals and M&A Medical technology

Today's news in brief

BioWorld

BioWorld briefs for April 10, 2026.

News in brief

BioWorld Asia

BioWorld Asia briefs for April 7, 2026

MMP inhibitors divulged in Accure Therapeutics patent

BioWorld Science

Accure Therapeutics has reported new oligopeptide derivatives acting as matrix metalloproteinase-2 (MMP-2) and MMP-9 inhibitors. As such, they are described as...

MSD discloses new HCN1/2 blockers

BioWorld Science

Merck Sharp & Dohme LLC (MSD) has synthesized new indazole derivatives acting as potassium/sodium hyperpolarization-activated cyclic nucleotide-gated channel 1...

Orexin OX2 receptor agonists disclosed in Vertex Pharmaceuticals patent

BioWorld Science

Vertex Pharmaceuticals Inc. has patented new macrocyclic sulfonamide orexin OX2 receptor agonists potentially useful for the treatment of amyotrophic lateral...